The emergence of multidrug-resistant (MDR) pathogens and cancers alarms the world for the urgent exploration of new therapeutic drugs to treat the superbugs and cancer patients. Since the ancient time, natural products and/or their derivatives have become continuous sources of leading commercialized pharmacological compounds that are used as antibiotics and antitumor agents. An unexplored source of natural products, lichen, currently has evolved into a propitious source of diverse secondary metabolites with various bio-activities including anticancer and antimicrobial, offering the abundant potentiality for future drugs. Herein, we summarized the progress in the discovery of structurally diverse anticancer compounds (C1-C85) with their plausible mode of action and antimicrobial compounds (M1-M112) from lichen and lichen-derived fungi together with their biodiversity. This review covers natural products discussed in literature from January 1985 to December 2017.
No takes yet. Share an insight, caveat, or question.
Basnet et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: